ARTICLE | Product Development

WHO prioritizing Gilead’s remdesivir, designing master protocol for 2019-nCoV outbreak

WHO plans to establish master protocol for 2019-nCoV outbreak

February 5, 2020 12:55 AM UTC
Updated on Mar 26, 2020 at 1:20 AM UTC

Gilead’s remdesivir is the most promising candidate for treating 2019-nCoV acute respiratory disease, according to a draft report of WHO’s R&D Blueprint Clinical Trials expert group.

The group agreed in principle to design a randomized, controlled master protocol that can compare multiple investigational therapies in parallel. ...